Payment overview · 2025
General Payments
$154.86
8 reported records · 7 companies
Healthcare provider profile · identity verified
Ryan Mark Harden, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SANDSTONE, MN · NPI 1295957116
Verified facts
What the public records show
CMS Open Payments records show Ryan Mark Harden, M.D. received $154.86 in general payments during 2025 across 8 reported records.
Xeris Pharmaceuticals, Inc. accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.76 | 25.7% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $28.94 | 18.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.66 | 13.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.89 | 12.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.97 | 11.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.41 | 9.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.23 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $154.86 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 548 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 526 | 120 |
| Losartan Potassium | Losartan Potassium | 397 | 84 |
| Lisinopril | Lisinopril | 356 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 286 | 67 |
| Furosemide | Furosemide | 261 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 254 | 41 |
| Omeprazole | Omeprazole | 244 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 39 |
| Gabapentin | Gabapentin | 192 | 43 |
| Metformin Hcl | Metformin Hcl | 187 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 38 |
| Sertraline Hcl | Sertraline Hcl | 150 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 35 |
| Eliquis | Apixaban | 128 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 25 |
| Celecoxib | Celecoxib | 110 | 24 |
| Pregabalin | Pregabalin | 110 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 23 |
| Allopurinol | Allopurinol | 101 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 25 |
| Simvastatin | Simvastatin | 97 | 23 |
| Alendronate Sodium | Alendronate Sodium | 88 | 19 |
| Trazodone Hcl | Trazodone Hcl | 86 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 19 |
| Potassium Chloride | Potassium Chloride | 80 | 15 |
| Tramadol Hcl | Tramadol Hcl | 76 | 22 |
| Terazosin Hcl | Terazosin Hcl | 75 | 13 |
| Xarelto | Rivaroxaban | 75 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | 20 |
| Prednisone | Prednisone | 55 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Jardiance | Empagliflozin | 54 | suppressed |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Atenolol | Atenolol | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 15 |
| Jantoven | Warfarin Sodium | 44 | 11 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | 12 |
| Montelukast Sodium | Montelukast Sodium | 43 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Nystatin | Nystatin | 41 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Famotidine | Famotidine | 35 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 14 |
| Ozempic | Semaglutide | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 32 | 11 |
| Torsemide | Torsemide | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Estradiol | Estradiol | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 14 |
| Nyamyc | Nystatin | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $154.86 · 8 records | Xeris Pharmaceuticals, Inc. | BREZTRI, KEVEYIS, Kerendia, VRAYLAR, Veozah, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error